公开(公告)号：US20240316008A1

公开(公告)日：2024-09-26

申请号：US18003153

申请日：2021-06-21

申请人： TRANQUIS THERAPEUTICS, INC.

发明人： Sanjay Kumar KAKKAR

IPC分类号： A61K31/4184 ,  A61P37/06

CPC分类号： A61K31/4184 ,  A61P37/06

摘要： The disclosure provides methods of treating a patient who has, or who is at risk for developing, systemic immune activation, including cytokine release syndrome (CRS) and sepsis. The method comprises administering a therapeutically effective amount of a compound of Formula I the patient.

公开(公告)号：US20240307356A1

公开(公告)日：2024-09-19

申请号：US18571177

申请日：2022-06-17

申请人： Tranquis Therapeutics, Inc.

发明人： Jonas O'Gara HANNESTAD ,  Steven August SMITH ,  Sanjay Kumar KAKKAR

IPC分类号： A61K31/4184 ,  A61K9/00 ,  A61P25/16 ,  A61P25/28

CPC分类号： A61K31/4184 ,  A61K9/0053 ,  A61P25/16 ,  A61P25/28

摘要： Methods are provided for reducing neuroinflammation and/or treating a neurodegenerative disease in a subject. The methods comprise orally administering to a subject with neuroinflammation and/or a neurogenerative disease a pharmaceutical composition comprising the compound of formula (I)




(TQS-168), or a pharmaceutically acceptable salt thereof, in amount that provides defined plasma and brain exposures of TQS-168 and/or an active metabolite following administration.